Source: EURLEX
Language: en
Format: md

[**Avis juridique important**](../../../editorial/legal_notice.htm)

*|*

# 92002E2860

**WRITTEN QUESTION E-2860/02 by Margrietus van den Berg (PSE) to the Commission. Absence of any annual report on the action programme to combat Aids.** 
  
*Official Journal 222 E , 18/09/2003 P. 0024 - 0025*

  

WRITTEN QUESTION E-2860/02

by Margrietus van den Berg (PSE) to the Commission

(10 October 2002)

Subject: Absence of any annual report on the action programme to combat Aids

The action programme to combat Aids was adopted on 21 February 2001. In February 2002 at a consultation meeting with the DG for Trade, NGOs were promised that a separate annual report on the first year of the action programme would be presented shortly.

This annual report is still not available and there are rumours that the action programme is merely to be included in the European Commission's general annual report.

1. Will the European Commission honour its promise to report separately on this action programme?

2. If not, why did it promise to do so earlier?

3. How does the European Commission define the word shortly?

Answer given by Mr Nielson on behalf of the Commission

(19 November 2002)

The Commission is currently finalising an extensive analysis of the Programme for Action, 18 months after its adoption. As the Programme for Action entails a series of new and important policy, programming and implementation initiatives, reporting will indeed be done this time separately from the Annual Report on the Development Policy.

The report is expected to be adopted in January 2003. The Commission will therefore keep its promise.

Reporting has been delayed mainly due to the Commission investing time and resources in the Global Fund to fight human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), tuberculosis (TB) and malaria, the follow-up to the Doha Declaration on Public Health and Trade Related Intellectual Property Rights (TRIPs), the establishment of the European and Developing Countries Clinical Trials Platform, the discussions in Parliament and Council on the Regulation for a special budget line for the Programme for Action, all of which are actions defined in the Programme for Action.

[Top](#document1)